Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

Ocular Therapeutix (NASDAQ: OCUL) will participate in scientific conferences and an investor conference during October 2026 in New Orleans and New York.

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) will participate in scientific conferences and an investor conference during October 2026 in New Orleans and New York. CEO Pravin U. Dugel will present a fireside chat at the Chardan 10th Annual Healthcare Conference on October 20 at 9:45 AM ET in New York.

Scientific appearances in New Orleans include Eyecelerator and Innovate Retina on October 8, followed by American Academy of Ophthalmology meetings. Scheduled presentations on October 8, 9 and 12 cover the Phase 3 SOL-1 trial; the announcement provides no trial results. Medical conference presentation times may change. The Chardan webcast will be available through the company's investor relations website, with a replay archived for at least 30 days.

Argus 15 min delay 1 alert

-0.72% vs previous close $7.62 last price 2.2x rel. volume Open Argus

Details

Market Reaction – OCUL

$7.43 – $7.88 Day Range

$1.67B Market Cap

On Oct 1, the day this news came out, the latest delayed price for OCUL is 0.72% below the previous close. The latest delayed price is $7.62. Relative volume is elevated at 2.2x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Terms

phase 3, intravitreal

2 terms

phase 3 medical

"Phase 3 Trial of OTX-TKI (SOL-1) for Wet AMD"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

intravitreal medical

"Evaluating Intravitreal Axitinib Hydrogel (OTX-TKI) in nAMD"

An intravitreal treatment is one given by injecting medicine directly into the gel-like center of the eye, delivering drugs straight to the site of retinal disease rather than through pills or eye drops. Investors care because this delivery method affects development costs, regulatory review, clinical risk, manufacturing and distribution complexity, and reimbursement — all factors that influence a therapy’s commercial potential.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BEDFORD, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific and investor conferences in October 2026.

Upcoming Investor Conference:

Chardan 10^th Annual Healthcare Conference:
Date: Tuesday, October 20, 2026
Fireside Chat: 9:45 AM ET
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: New York, NY

A live webcast of the Chardan fireside chat can be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page. A replay of the webcasts will be archived for at least 30 days following the presentation.

Upcoming Scientific Conferences:

Eyecelerator @ AAO 2026: October 8, 2026
New Orleans, Louisiana

• Company Presentation: Ocular Therapeutix: Redefining the Retina Experience
  Session: Retina-Biologics, Diagnostics, & AI Showcase
  Session Date/Time: Thursday, October 8, 2026, 1:43 – 1:48 PM CT
  Presenter: Peter K. Kaiser, MD, Chief Development Officer

• Panel Discussion: The Odyssey: Industry Heroes Seeking Safe Passages and Happy Returns
  Panel Date/Time: Thursday, October 8, 2026, 3:45 – 4:30 PM CT
  Panelist: Pravin U. Dugel, MD, Executive Chairman, President and CEO

Innovate Retina: October 8, 2026
New Orleans, Louisiana

• Presentation: Sustained Hydrogel Delivery in Neovascular AMD: Topline Outcomes from the Phase 3 SOL-1 Trial with Hydrogel-Formulated Axpaxli
  Session: Ocular Gene Therapies & Advanced Therapeutics
  Session Date/Time: Thursday, October 8, 2026, 5:35 – 5:39 PM CT
  Presenter: Arshad M. Khanani, MD, MA, FASRS

• Panel Discussion
  Session: Industry Insights & Advanced Therapeutics
  Panel Date/Time: Thursday, October 8, 2026, 6:45 – 7:15 PM CT
  Panelist: Peter K. Kaiser, MD, Chief Development Officer

American Academy of Ophthalmology Retina Subspeciality Day: October 9 - 10, 2026
New Orleans, Louisiana

• Presentation: Phase 3 Trial of OTX-TKI (SOL-1) for Wet AMD
  Session: Section X: Clinical Trial Updates, Part I
  Presentation Date/Time: Friday, October 9, 2026, 4:35 – 4:40 PM CT
  Presenter: Darius M. Moshfeghi, MD, FASRS

American Academy of Ophthalmology: October 9-12, 2026
New Orleans, Louisiana

• Presentation: Redefining the Management of nAMD: The Impact of Durability and Sustained Disease Control
  Session: Industry Showcase
  Session Date/Time: Saturday, October 10, 2026, 11:30 AM – 12:30 PM CT
  Faculty: Arshad M. Khanani, MD, MA, FASRS; Mark R. Barakat, MD, FASRS; Dilsher S. Dhoot, MD, FASRS

• Presentation: SOL-1 Phase 3 Superiority Trial Evaluating Intravitreal Axitinib Hydrogel (OTX-TKI) in nAMD
  Presentation Date/Time: Monday, October 12, 2026, 9:00 – 9:07 AM CT
  Presenter: Mark R. Barakat, MD, FASRS

Exact medical conference presentation times may be subject to change.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com